PCSK9 anticorps (AA 231-330) (Alexa Fluor 488)

N° du produit ABIN910346

Détail du produit anti-PCSK9 anticorps (Alexa Fluor 488)

Antigène: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Épitope: AA 231-330

Reactivité: Humain, Rat, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PCSK9 est conjugé à/à la Alexa Fluor 488

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Réactivité croisée: Humain, Souris, Rat

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human PCSK9/NARC1

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur PCSK9

Antigène: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Autre désignation: NARC1 (PCSK9 Produits)

Synonymes: anticorps FH3, anticorps HCHOLA3, anticorps LDLCQ1, anticorps NARC-1, anticorps NARC1, anticorps PC9, anticorps AI415265, anticorps AI747682, anticorps Narc1, anticorps proprotein convertase subtilisin/kexin type 9, anticorps proprotein convertase subtilisin/kexin type 9 L homeolog, anticorps PCSK9, anticorps pcsk9.L, anticorps pcsk9, anticorps Pcsk9

Sujet:

Synonyms: FH3, PC9, NARC1, LDLCQ1, NARC-1, HCHOLA3, Proprotein convertase subtilisin/kexin type 9, Neural apoptosis-regulated convertase 1, Proprotein convertase 9, Subtilisin/kexin-like protease PC9, PCSK9, PSEC0052

Background: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

ID gène: 255738

UniProt: Q8NBP7